NCT00791154View on ClinicalTrials.gov

QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

December 2, 2008

Primary Completion Date

February 2, 2010

Study Completion Date

May 1, 2013

Conditions
Lung CancerSmall Cell Lung CancerSolid TumorsExtensive-stage Small Cell Lung Cancer
Interventions
DRUG

AMG 479

AMG 479 is administered to subjects

DRUG

Etoposide

Etoposide is administered to subjects

DRUG

Placebo

Placebo is administered with Carboplatin and Etoposide

DRUG

AMG 102

AMG 102 is administered to subjects

DRUG

Carboplatin

Carboplatin is administered to some subjects in combination

DRUG

Cisplatin

Cisplatin is administered to some subjects in combination

Sponsors

Lead Sponsor

NantCell, Inc.
All Listed Sponsors
lead

NantCell, Inc.

INDUSTRY

NCT00791154 - QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter